Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
3.8 ^USD	-1.30%		-7.99%	-22.13%

Apr. 05	Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale	CI
Mar. 06	JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating	MT

Akoya Biosciences, Inc. Appoints Myla Lai-Goldman to Its Board of Directors

September 22, 2021 at 08:05 am EDT

Akoya Biosciences, Inc. announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors. Dr. Lai-Goldman is currently the Chair of GeneCentric Therapeutics.

Latest news about Akoya Biosciences, Inc.

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale	Apr. 05	CI
JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating	Mar. 06	MT
UBS Adjusts Akoya Biosciences Price Target to $7.50 From $7, Maintains Buy Rating	Mar. 05	MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	Mar. 04	CI
Transcript : Akoya Biosciences, Inc., Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q4 Revenue $26.5M, vs. Street Est of $26.1M	Mar. 04	MT
Akoya Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 04	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Transcript : Akoya Biosciences, Inc. - Special Call	Feb. 28
Transcript : Akoya Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Akoya Biosciences, Inc. Announces Board Changes	Jan. 10	CI
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal	Jan. 08	DJ
Akoya Biosciences Expects 20% Revenue Growth in 2024; Shares Gain Premarket	Jan. 08	MT
Akoya Biosciences Unveils Algorithm for Integration of Spatial, Single-Cell Data; Shares Jump Premarket	Jan. 08	MT
Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform	Jan. 07	CI
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024	Jan. 07	CI
Akoya Biosciences, Inc. and Thermo Fisher Scientific, Inc. Announce License and Distribution Agreement to Deliver Spatial Multiomics Workflow	Jan. 07	CI
Stephens Adjusts Price Target on Akoya Biosciences to $9 From $14, Maintains Overweight Rating	Nov. 13	MT
Transcript : Akoya Biosciences, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Akoya Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q3 Revenue $25.2M, vs. Street Est of $24.5M	Nov. 08	MT
Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023	Nov. 08	CI
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023	23-10-31	CI
Morgan Stanley Adjusts Akoya Biosciences' Price Target to $8 From $15, Keeps Overweight Rating	23-10-24	MT
UBS Cuts Akoya Biosciences Price Target to $7 From $12, Maintains Buy Rating	23-10-12	MT

Chart Akoya Biosciences, Inc.

Duration

Period

More charts

Company Profile

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Akoya Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.8 USD

Average target price

9 USD

Spread / Average Target

+136.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AKOYA BIOSCIENCES, INC.	-22.13%	187M
THERMO FISHER SCIENTIFIC	+2.64%	208B
DANAHER CORPORATION	+1.80%	174B
INTUITIVE SURGICAL, INC.	+8.59%	130B
BOSTON SCIENTIFIC CORPORATION	+16.47%	98.97B
SIEMENS HEALTHINEERS AG	-3.42%	60.46B
EDWARDS LIFESCIENCES CORPORATION	+12.71%	51.73B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.61%	45.33B
AGILENT TECHNOLOGIES, INC.	-4.53%	38.9B
GE HEALTHCARE TECHNOLOGIES INC.	+9.27%	38.56B

Other Advanced Medical Equipment & Technology